These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 36318701

  • 1. Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States.
    Pizzicato LN, Vadhariya A, Birt J, Ketkar AG, Bolce R, Grabner M, Pepe RS, Walsh JA.
    J Manag Care Spec Pharm; 2023 Jan; 29(1):24-35. PubMed ID: 36318701
    [Abstract] [Full Text] [Related]

  • 2. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
    Blauvelt A, Shi N, Zhu B, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Murage MJ.
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
    [Abstract] [Full Text] [Related]

  • 3. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ, Princic N, Park J, Malatestinic WN, Zhu B, Atiya B, Kern SA, Stenger KB, Sprabery AT, Ogdie A.
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [Abstract] [Full Text] [Related]

  • 4. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ, Lee J, Knievel K, McVige J, Wang W, Wu Z, Gillard P, Shah D, Blumenfeld AM.
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [Abstract] [Full Text] [Related]

  • 5. Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
    Walsh JA, Adejoro O, Chastek B, Palmer JB, Hur P.
    J Manag Care Spec Pharm; 2018 Jul; 24(7):623-631. PubMed ID: 29952704
    [Abstract] [Full Text] [Related]

  • 6. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, Ganguli A, Fendrick AM.
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [Abstract] [Full Text] [Related]

  • 7. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M.
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [Abstract] [Full Text] [Related]

  • 8. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
    Blauvelt A, Shi N, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Zhu B, Murage MJ.
    J Am Acad Dermatol; 2020 Apr; 82(4):927-935. PubMed ID: 31712178
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: a Danish population-based cohort study.
    Hansen RL, Jørgensen TS, Egeberg A, Rosenø NAL, Skougaard M, Stisen ZR, Dreyer L, Kristensen LE.
    Rheumatology (Oxford); 2024 May 03; 63(6):1593-1598. PubMed ID: 37647648
    [Abstract] [Full Text] [Related]

  • 11. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
    Blauvelt A, Burge R, Malatestinic W, Brnabic A, Guo J, Janardhanan M, Zhu B.
    J Manag Care Spec Pharm; 2021 Jan 03; 27(1):84-94. PubMed ID: 33377444
    [Abstract] [Full Text] [Related]

  • 12. Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study.
    Joven B, Manteca CF, Rubio E, Raya E, Pérez A, Hernández R, Manrique S, Núñez M, Díaz-Cerezo S, Moyano S, Lacetera A, García-Vicuña R.
    Adv Ther; 2023 Dec 03; 40(12):5415-5431. PubMed ID: 37804475
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.
    Zhang J, Sridhar G, Barr CE, Eichelberger B, Lockhart CM, Marshall J, Clewell J, Accortt NA, Curtis JR, Holmes C, McMahill-Walraven CN, Brown JS, Haynes K.
    J Manag Care Spec Pharm; 2020 Apr 03; 26(4):417-490. PubMed ID: 32223608
    [Abstract] [Full Text] [Related]

  • 15. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ, Keyloun KR, Higa S, Park J, Bonafede M, Gillard P, Jain R.
    J Manag Care Spec Pharm; 2022 Dec 03; 28(12):1335-1343. PubMed ID: 36427344
    [Abstract] [Full Text] [Related]

  • 16. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.
    Blauvelt A, Shi N, Somani N, Burge R, Zhu B, Ridenour TL, Lew CR, Zimmerman NM, Atiya B, Murage MJ.
    J Am Acad Dermatol; 2022 Mar 03; 86(3):581-589. PubMed ID: 34252464
    [Abstract] [Full Text] [Related]

  • 17. Health care utilization and costs associated with functional status in patients with psoriatic arthritis.
    Ogdie A, Hwang M, Veeranki P, Portelli A, Sison S, Shafrin J, Pedro S, Hass S, Hur P, Kim N, Yi E, Michaud K.
    J Manag Care Spec Pharm; 2022 Sep 03; 28(9):997-1007. PubMed ID: 36001101
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
    Malatestinic W, Nordstrom B, Wu JJ, Goldblum O, Solotkin K, Lin CY, Kistler K, Fraeman K, Johnston J, Hawley LL, Sicignano N, Araujo A.
    J Manag Care Spec Pharm; 2017 Mar 03; 23(3):370-381. PubMed ID: 28230450
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.